The company, which planted some of the earliest seeds that prescription smartphone apps could stand alongside prescription drugs, filed for Chapter 11 bankruptcy, and announced it would lay off more than 90% of its employees as it seeks a buyer.

Late last year, C2N Diagnostics unveiled the second generation of its liquid biopsy technology to screen for Alzheimer’s disease, and now, it’s putting that blood test to the test.

Almost 500 days have gone by since Molecular Templates disclosed the second of two cardiac adverse events in recipients of its CD38-directed cancer candidate. The biotech dialed down the dose at the start of 2022, and the trial has progressed uneventfully since then. Nonetheless, the FDA has now slapped a partial hold on the study and asked for information such as the justification for the revised dose.

Two weeks after the World Health Organization revised its guidance on COVID-19 vaccination, data analytics company GlobalData says the future of vaccine rollouts is becoming “highly uncertain.”

After bursting out of stealth last year with the landscape-shifting claim that it had developed a whole-genome sequencing platform that can run analyses for only $100 apiece, Ultima Genomics is now working to get that technology into the hands of those who need it most.

Regeneron’s first-quarter earnings are expected to take a $56 million hit tied to in-process research and development costs for a freshly inked autoimmune deal with Sonoma Biotherapeutics.